New treatments in membranous glomerulopathy – from the pitfalls of rituximab to a new era of biological treatments

Filipa Ferreira, Ana Teresa Nunes
Nephrology department, Centro Hospitalar de São João – Porto, Portugal

ABSTRACT

Primary membranous nephropathy (PMN) is the main cause of nephrotic syndrome in adults. The recognition that this kidney-specific disease is the result of an autoimmune process has changed diagnostic and therapeutic approaches. The determination of anti-phospholipase A2 receptor and thrombospondin type-1 domain containing 7A, when available, are part of the diagnostic and therapeutic monitoring workup. More recently, more putative antigens have been discovered.

Treatment of PMN relies on optimal supportive care but immunosuppression is indicated in patients at risk of progressive kidney injury. Immunosuppression schemes commonly used are cyclophosphamide/steroids (modified Ponticelli), calcineurin inhibitors/steroids and, after the MENTOR trial, rituximab has also been considered a first-line agent in non-severe cases. However, even in the MENTOR trial, 40% of patients did not achieve remission.

Rituximab-resistant PMN cases have been published. Many mechanisms have been implicated in rituximab resistance, such as the development of anti-drug antibodies, interindividual variability in drug levels, consumption of drug by internalization of the complex rituximab-CD20, the pool of autoreactive B-cells that is in circulation available for drug action, drug wasting in urine through proteinuria and also epitope spreading.

Recognition and knowledge of some of these specific mechanisms of resistance has led to the use of other biologic agents. New monoclonal antibodies targeting CD20 have been developed and can be a rescue therapy for resistance PMN cases. However, as even these new-generation agents do not target memory plasma cells, therapies targeting these cells are promising. Inhibition of factors that activate autoreactive B-cells may also become an option. Additionally, a better understanding of the complement-mediated mechanisms of injury in PMN may bring to the pipeline novel biological therapies for this disease.

Key-words: Autoantibodies; glomerulonephritis, membranous; rituximab.
represent potential biomarkers or target antigens in secondary autoimmune MN.

A third new protein has been reported, Semaphorin 3B, that appears to be almost exclusive in pediatric patients\(^9\).

Treatment of PMN relies on optimal supportive care (SC), including blood pressure control, minimization of proteinuria through renin-angiotensin-aldosterone blockage, and control of nephrotic syndrome complications. In patients with persistent nephrotic syndrome, up to 40% will progress to kidney failure within 10 years\(^5\). Immunosuppression is therefore recommended for patients considered at risk of progressive kidney injury (persistent proteinuria, progressive decline in glomerular filtration rate (GFR) after 3-6 months of SC and/or high titers of anti-PLA2R). Immunosuppression schemes commonly used are cyclophosphamide/steroids (modified Ponticelli), which is considered the first-line regimen in the 2012 KDIGO guidelines, calcineurin inhibitors (CNIs)/steroids, and more recently rituximab\(^10\). Rituximab can trigger B-cell death, and in consequence antibody production, by apoptosis, complement-mediated cytotoxicity, and antibody-dependent cellular cytotoxicity (ADCC)\(^11\). B-cell therapy has gained ground as an option for MN in the last years, after some observational data\(^12-15\), but it was the MENTOR trial\(^16\) that placed rituximab as a viable candidate for first-line treatment. Fervenza et al. showed that this anti-CD20 agent was non-inferior to cyclosporin in inducing proteinuria remission at 12-months, and was superior in maintaining proteinuria remission (60% versus 20% clinical remission) up to 24 months, in patients at high risk of progressive disease. Additionally, the incidence of adverse events was similar in the two groups, but serious adverse events were more common in the cyclosporin group. The upcoming KDIGO clinical guidelines for glomerular diseases have already contemplated rituximab as a first-line option for MN, as an alternative for cyclophosphamide. However, in very high-risk patients, cyclophosphamide is still the preferred treatment\(^6\).

Despite the encouraging results of the MENTOR trial, one should not lose sight of the fact that 40% of patients receiving rituximab had treatment failure. The authors suggest that this high incidence of treatment failure may be overestimated due to the shorter follow-up period, arguing that proteinuria decline is gradual and the nadir may not be reached until 36 months after the initiation of treatment.

Noteworthy is the value of B-cell depletion monitoring, by CD19-cell counts, as a surrogate marker of rituximab response. This question hasn’t been fully addressed as of yet but the KDIGO guidelines highlight that CD19 counts are not sufficient to judge rituximab efficacy\(^6\).

Notwithstanding, rituximab-resistant MN cases have been published\(^17-19\) and there is a need for alternative therapies for these patients. Rituximab resistance has been somewhat arbitrarily defined but is generally accepted as a lack of response or overt progression during or within 6 months of completion of a rituximab-containing regimen\(^20\). However, one should recognize that the persistence of proteinuria may not correspond to treatment resistance but, for instance, secondary segmental sclerosis development. Other clinical parameters, such as serum albumin, are important to the differential diagnosis and it may be reasonable to perform a second kidney biopsy.

### Table I

Potential causes of rituximab-resistant primary membranous nephropathy

<table>
<thead>
<tr>
<th>Anti-drug antibodies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interindividual variability in rituximab levels</td>
</tr>
<tr>
<td>Gender</td>
</tr>
<tr>
<td>Polymorphism in FcγRIIIa protein, CD11b, FcRn</td>
</tr>
<tr>
<td>Consumption of rituximab by internalization of the complex rituximab-CD20</td>
</tr>
<tr>
<td>Pool of autoreactive B-cells that is in circulation available for drug action</td>
</tr>
<tr>
<td>Drug wasting in urine</td>
</tr>
<tr>
<td>Epitope spreading</td>
</tr>
</tbody>
</table>

Several explanations have been postulated for truly rituximab-resistant cases (Table I).

The development of anti-drug antibodies is one of the proposed mechanisms. Rituximab is a chimeric monoclonal antibody including a human IgG1 constant region and a murine anti-human CD20 variable region that can elicit an immune response. Boyer-Suvaet and colleagues\(^18\) found neutralizing anti-rituximab antibodies in 10 (22.7%) out of 44 idiopathic membranous patients 6 months after one rituximab course (2 perfusions of 1g at 2-weeks interval). These patients had higher levels of CD19 counts at month 6, meaning faster B-cells reconstitution. Interestingly, remission rate was not different according to the presence or not of anti-rituximab antibodies, but relapses were more frequent in patients with anti-drug antibodies. These immunized patients have also required a higher number of rituximab infusions. In the future, we hope that anti-rituximab antibodies assays are available for daily clinical practice so we can tailor therapy.

Interindividual variability in rituximab levels is another factor that can explain differences in response to this agent. Most studies and published data refer to lymphoma and rheumatologic patients but one can extrapolate some findings to MN patients. Gender is a constitutive parameter that seems to influence drug pharmacokinetics, with men having a higher clearance of rituximab than women. Moreover, polymorphisms that are functionally relevant to the rituximab mode of action have been identified. There is a polymorphism described in the gene encoding FcyRlla protein that alters its affinity for IgG1, thus diminishing affinity for rituximab. It is present in monocytes/macrophages and natural killer cells and is responsible for activation of ADCC, one of the mechanisms elicited by rituximab for inducing B-cells death. The genetic heterogeneity of CD11b, which plays a major role in rituximab’s complement-enhanced ADCC (CR3-ADCC), may also influence response to this drug. Also, the variability in the neonatal Fc receptor (FcRn), the endothelial cell receptor responsible for rituximab (and other drugs) recycling mechanism (Figure 1), may explain differences in rituximab response\(^21\). The internalization of the complex rituximab-CD20 is one possible explanation for resistance to rituximab over time (Figure 1). This process leads to degradation of the CD20-rituximab complexes and therefore less recruitment of macrophages and consequently less antibody-dependent phagocytosis\(^22\). Some authors suggest that its efficacy can be enhanced by blocking the pathways involved in this process\(^23\). There is another factor that can influence response to anti-CD20 agents such as rituximab, which is the pool of autoreactive B-cells that is in circulation.
versus the pool that may chiefly reside in secondary lymphoid organs, thus being less available for drug action. An observation study (PEP-TIDE, NCT04095156) is ongoing, aiming to analyze the circulating immune repertoire of MN patients before and after the infusion of B-cell lineage depleting agents, assessing the presence of circulating PLA2R autoreactive B cells from appropriately stratified responder and non-responder patients. MN patients have an additional mechanism for lower rituximab levels related to proteinuria and drug wasting in urine. Jacobs and colleagues evaluated urinary rituximab and total IgG levels in nephrotic patients previously treated with this agent. Urinary rituximab levels were detected in all patients, proving that measurement of urinary drug levels by flow cytometry is feasible. Moreover, the authors suggest that a correlation between total urinary IgG and rituximab levels may exist, but more studies are needed to elucidate this. In that case, the analysis of total IgG in urine, which can be easily performed in standard laboratories, might be sufficient to predict the probability of rituximab loss during treatment, and adjust posology.

Another explanation for the variable response to rituximab is related to epitope spreading. Epitope spreading is an immunologic phenomenon whereby an antibody or cellular response to a given antigen may extend from one location on the antigen (epitope) to involve other region(s) of the same antigen (intramolecular spreading) or adjacent antigens (intermolecular spreading) as the immune response matures. In the case of PMN, autoantibodies firstly involved are typically directed to the cysteine-rich domain (CysR) of the PLA2R, and then extend to other epitopes on the same protein, commonly C-type lectin domains (CTLD) 1 and 7. Seitz-Polinski et al. showed that patients with anti-CysR-restricted activity had a better renal prognosis than patients that had epitope spreading beyond the CysR, who were less likely to achieve spontaneous remission. The same authors have shown that rituximab not only decreases anti-PLA2R titers but also reverses epitope spreading. However, to achieve this, it seems that higher doses of rituximab (two infusions of 1g 2-weeks apart versus four doses of 375 mg/m² at 1- to 2-week intervals) are needed. This paper has highlighted the influence of epitope spreading on
treatment resistance and suggested that a higher dose of rituximab is needed in spreaders.

Recognition and knowledge of some of these specific mechanisms of resistance has led to the development of other anti-B-cell agents (Table II). New monoclonal antibodies targeting CD20 are currently used in non-Hodgkin lymphomas and autoimmune diseases, including two humanized IgG1, obinutuzumab and ocrelizumab (Roche®), and a fully-human IgG1, ofatumumab (GSK®).

### Table II

<table>
<thead>
<tr>
<th>New anti-CD20 mAbs</th>
<th>Plasma-cell-depleting therapies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obinutuzumab – ongoing phase III double-blind RCT (REGENCY)</td>
<td>Delanzomib</td>
</tr>
<tr>
<td>Ocrelizumab</td>
<td>Carfilzomib</td>
</tr>
<tr>
<td>Ofatumumab</td>
<td>Bortezomib</td>
</tr>
<tr>
<td></td>
<td>MOR202 – ongoing phase Ib/IIa open-label clinical trial (M-PLACE)</td>
</tr>
<tr>
<td><strong>Proteasome inhibitors</strong></td>
<td><strong>Plasma-cell-depleting therapies</strong></td>
</tr>
<tr>
<td>Bortezomib</td>
<td>Delanzomib</td>
</tr>
<tr>
<td>Carfilzomib</td>
<td>Blys/BAF inhibitor</td>
</tr>
<tr>
<td>Dataturumab</td>
<td>Belimumab – ongoing double-blind RCT (REBOOT)</td>
</tr>
<tr>
<td>Isatuximab</td>
<td><strong>Legend:</strong> BlyS, B-lymphocyte stimulator; RCT, randomized clinical trial</td>
</tr>
<tr>
<td>MOR202 – ongoing phase Ib/IIa open-label clinical trial (M-PLACE)</td>
<td></td>
</tr>
</tbody>
</table>

Obinutuzumab is a humanized type II anti-CD20 monoclonal antibody (mAb). Type II mAbs, compared to type I, elicit little modulation of CD20 from the cell surface, thus having less consumption through internalization process, and have a higher affinity toward ADCC-induced death. The glycosylation of the molecule confers a better binding of effector immune cells and therefore higher ADCC and less dependence on CDC, compared to rituximab. Despite this theoretical advantage, the clinical benefits have been variable (28). It also induces a direct cell death mediated by lysosomes and less dependence on high levels of B-cell activating factor, which contributes to a greater depletion of memory B cells that classically are more resistant to the effect of rituximab (23). Obinutuzumab has already been successfully used in resistant MN cases. Klonjít et al. (19) published a case report of 3 patients with PLA2R-associated MN that failed to respond to rituximab but who were successfully treated with this new anti-CD20, achieving partial clinical remission. Two of the three patients have also achieved immunologic remission and the third one, despite not fulfilling the restricted criteria of immunologic remission, had a dramatic decrease in anti-PLA2R titers. Moreover, the effect of obinutuzumab appears to be long-lasting, since one patient remained in clinical remission as long as 24 months after one course of the drug. There is an ongoing phase III double-blind randomized controlled trial (REGENCY, NCT04221477) assessing the efficacy, safety, and pharmacokinetics of obinutuzumab compared with placebo in patients with class III or IV lupus nephritis when added on to standard-of-care therapy consisting of mycophenolate mofetil and corticosteroids.

Ofatumumab binds to a different epitope than rituximab, as it can bind both the small and large extracellular loops of CD20, which may be the reason for increased complement-dependent cytotoxicity (CDC) activity compared to rituximab (28). Moreover, it has a higher avidity for CD20 molecule compared to rituximab, being able to induce cell death even in cells with a lower density of CD20 (29). This latter mechanism is thought to be the reason for rituximab resistance in some hematologic malignancies. Because ofatumumab is fully-human, anaphylaxis is expected to be less common. This drug has shown efficacy in the treatment of B-cell lymphomas and other hematologic malignancies which had previously not responded to rituximab. Ofatumumab has been used as a rescue therapy for patients with MN in whom retreatment with rituximab is contraindicated due to drug-related immune-complex mediated hypersensitivity reaction (30). Podesta and colleagues (31) presented a case report of 3 patients in whom they tried ofatumumab and double-filtration plasmapheresis (DFPP) as a treatment for PMN. The best results were achieved with ofatumumab administration previous to DFPP, with a significant reduction in anti-PLA2R titers. This agent could be a safe and cost-effective rescue therapy for patients with MN sensitized against rituximab.

Whether new second and third generation anti-CD20 mAbs can achieve higher rates of sustained complete remission than rituximab remains to be determined, but such agents do not target long-lived memory plasma cells. In this field, plasma-cell-depleting therapies are promising. Plasma cells express CD38, which can be a target for anti-CD38 mAbs, such as dataturumab and isatuximab (Table II). Less specific proteasome inhibitors (with anti-B and anti-T cell activities) such as bortezomib, and second-generation proteasome inhibitors with equal efficacy but improved safety profile, such as delanzomib and carfilzomib, are also options. Currently, published data regarding bortezomib usage in PMN is limited to a few case reports (32,33). An open-label phase Ib/IIa clinical trial is currently running to characterize the safety and efficacy of the human anti-CD38 antibody MOR202 in patients with newly diagnosed, relapsed or refractory anti-PLA2R positive MN (M-PLACE, NCT04145440).

Another possible route for the treatment of MN patients is by inhibition of factors that activate autoreactive B cells (table II). BAFF (B cell-activating factor), also called B-lymphocyte stimulator (Blys), and APRIL (a proliferation-inducing ligand) are members of the tumor necrosis factor (TNF) superfamily. Their main functions are to modulate survival and differentiation of B lymphocytes. A study has evaluated the relationship between these cytokines levels, anti-PLA2R titers, and clinical outcomes in PMN patients. They reported that anti-PLA2R positive patients had higher levels of BAFF and APRIL than negative patients. Cytokines levels decreased after 6 months of immunosuppressive therapy but the reduction was less pronounced in patients that were still anti-PLA2R positive at the end of the 6-month immunosuppression course. They suggest that serum levels of both BAFF/Blys and APRIL may play a role as predictors of anti-PLA2R seroconversion and good clinical outcomes in patients with PMN (34). Belimumab, a human IgG1-k monoclonal antibody anti-Blys (BAff), has been approved for treatment of seropositive systemic lupus erythematosus patients and has been shown to reduce both disease activity and autoantibody levels (35). An experimental study has demonstrated a reduction in proteinuria and circulating levels of anti-PLA2R by 86 and 97%, respectively, in anti-PLA2R-positive PMN patients with
nephrotic-range proteinuria, the effects continuing up to 2 years of treatment with belimumab18. The REBOOT trial (NCT03949855) may bring more data about this agent in NM.

Finally, significant complement activation is present in MN as evidenced by large spectral counts of complement components from C3- and C4-based pathways, including regulatory proteins of complement pathways. Ravindran et al.37 reported that the entire complement cascade is active, with both the classical/lectin and alternative pathways driving and contributing to activation of the terminal pathway. Another study in an experimental membranous nephropathy model revealed that the activation of the alternative pathway is essential for the development of proteinuria28. A better understanding of the complement-mediated mechanisms of injury in MN may help develop novel biological therapies for this disease.

In conclusion, a better understanding of the pathogenic mechanisms involved in PMN has allowed the development of new therapeutic agents. Monoclonal antibodies are now part of the therapeutic armamentarium involved in PMN has allowed the development of new therapeutic agents. Monoclonal antibodies are now part of the therapeutic armamentarium for this disease.

**Disclosure of potential conflicts of interest:** none declared

**References**


**Correspondence to:** Ana Filipa da Silva Ferreira, MD

Nephrology department, Centro Hospitalar de São João

Alameda Prof. Hernâni Monteiro, 4200-319, Porto, Portugal

E-mail: filipasilvaf@gmail.com